- Home
- STKS vs MREO Comparison
STKS vs MREO Comparison
Compare STKS & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STKS | MREO |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.7M | 50.3M |
| IPO Year | 2011 | 2017 |
Fundamental Metrics
Financial Performance| Metric | STKS | MREO |
|---|---|---|
| Price | $1.64 | $0.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $4.70 | $1.50 |
| AVG Volume (30 Days) | 18.9K | ★ 4.9M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $805,722,000.00 | $500,000.00 |
| Revenue This Year | $7.47 | $5,184.20 |
| Revenue Next Year | $8.12 | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.66 | N/A |
| 52 Week Low | $1.63 | $0.20 |
| 52 Week High | $3.38 | $2.37 |
Technical Indicators
Market Signals| Indicator | STKS | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 39.37 | 41.16 |
| Support Level | N/A | $0.22 |
| Resistance Level | $1.87 | $0.35 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 10.26 | 23.31 |
Price Performance
Historical ComparisonAbout STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).